Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sławomir Milczarek has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Berubicin Substituted for Cytarabine in a MATRix-Based Regimen for Isolated Central Nervous System Lymphoma: A Five-Patient Case Series from the BER-PUM Study

    by Sławomir Milczarek, Oliwia Piotrowska, Bartłomiej Baumert, Ewa Borowiecka, Krzysztof Sommerfeld, Alina Hnatyszyn, Bogusław Machaliński

    Primary and isolated secondary central nervous system lymphomas are aggressive malignancies requiring effective central nervous system–directed therapy. Intensive high-dose methotrexate–based regimens may be difficult to deliver, particularly in older or functionally impaired patients. Berubicin is a doxorubicin analog developed to cross the blood–brain barrier. We report a prospective case series of five adults with primary or isolated secondary CNS lymphoma treated within the BER-PUM phase Ib/II study (EudraCT 2021-006028-41), evaluating berubicin as part of the investigational MBTRIX regimen. Patients received up to four 21-day cycles of rituximab, high-dose methotrexate, berubicin, and thiotepa, with between-patient and intrapatient berubicin dose escalation. Four out of five patients completed all planned cycles, even though most of the patients had an ECOG score of 2. After two cycles, four achieved partial response, and one had progressive disease. Two patients underwent autologous stem-cell transplantation; one achieved complete response maintained at 12 months, whereas the other died from severe infectious and multiorgan complications. All patients experienced at least one grade ≥ 3 adverse event, predominantly hematologic. No protocol-defined dose-limiting toxicity or berubicin dose reduction occurred. Recruitment ended prematurely because berubicin became unavailable. This case series demonstrates the feasibility of MBTRIX, although the small sample and incomplete dose escalation preclude definitive conclusions regarding safety and efficacy.

  • Open Access

    Vascular Access Devices for Stem Cell Transplantation: A Review of Catheter Types—A Crucial Step Towards the Enhancement of Patient Care

    by Sławomir Milczarek, Piotr Kulig, Oliwia Piotrowska, Alina Zuchmańska, Martyna Brzosko, Bogusław Machaliński

    Central venous access devices (CVADs) play a pivotal role in managing stem cell recipients, providing reliable access for the administration of chemotherapy, blood products, progenitor infusion, parenteral nutrition, and other crucial treatments. This review critically evaluates the various types of CVADs commonly employed in transplant settings, examining their indications, complications, and best practices to enhance patient outcomes. Moreover, it emphasizes the significance of broadening the selection algorithm for vascular devices and incorporating patient expectations and comfort into routine clinical practice.


  • Open Access

    Incidence of Catheter-Associated Bloodstream Infections in Stem Cell Recipients—Should We Be “PICCy”?

    by Sławomir Milczarek, Piotr Kulig, Oliwia Piotrowska, Alina Zuchmańska, Ewa Wilk-Milczarek, Bogusław Machaliński

    The management of patients undergoing HSCT requires a multipurpose central venous catheter. Peripheral catheters (PCs), such as peripherally inserted central catheters (PICCs) and MidLine catheters (MLCs), appear to be adequate vascular catheters to be used for stem cell infusion, although their utilization in this indication is not yet common. We analyzed the infectious complications such as blood stream infection (BSI), febrile neutropenia (FN) and central line-associated bloodstream infection (CLBSI) in patients undergoing stem cell infusion through PC and conventionally inserted central catchers (CICCs), and evaluated their impacts on transplantation outcomes. Our results reveal no statistically significant differences between different types of catheter in terms of FN, BSI and CLABSI. Moreover, transplantation outcomes were comparable between the groups. Interestingly, according to our data, there were no differences in terms of abovementioned infectious complications between individuals who received antibiotic prophylaxis and those who did not. Our study has shown that infection complications are independent of the intravenous device and antibiotic prophylaxis. Considering that PCs are not associated with life-threatening complications, they should be considered more frequently in the stem cell transplantation setting.


  • Open Access

    Catheter-related thrombosis in stem cell recipients: comparison of different types of catheter

    by Slawomir Milczarek, Piotr Kulig, Oliwia Piotrowska, Alina Zuchmanska, Anna Bielikowicz, Bogusław Machalinski


  • Open Access

    Safety of Cryopreserved Stem Cell Infusion through a Peripherally Inserted Central Venous Catheter

    by Sławomir Milczarek, Piotr Kulig, Alina Zuchmańska, Bartłomiej Baumert, Bogumiła Osękowska, Anna Bielikowicz, Ewa Wilk-Milczarek, Bogusław Machaliński

    The management of patients undergoing stem cell transplantation requires a multipurpose central venous catheter (CVC) to facilitate drug administration, parenteral nutrition, transfusion of blood products, and collection of blood samples. Peripherally inserted central venous catheters (PICCs) appear to meet these requirements but are rarely used for stem cell infusion. We aimed to retrospectively assess the safety and feasibility of stem cell infusion through PICC and to evaluate its impact on transplantation kinetics. We retrospectively analyzed the outcomes of peripheral blood stem cell (PBSC) transplantation in patients receiving cryopreserved autologous or allogeneic PBSC by PICCs and compared the results with patients receiving transplants through a conventionally inserted central venous catheter (CICC). Despite statistically significant differences in CD34+ dose, infusion rate, and total length of administration, the clinical outcomes of transplantation, exemplified by platelet and neutrophil engraftment, along with the length of hospitalization, were not affected by the prolonged infusion time and lower infusion velocity in the PICC group. Our study showed that the clinical outcomes of PBSC transplantation did not differ between the PICC and CICC groups, suggesting that both types of catheters can be implemented in a PBSC transplantation setting.


  • Open Access

    Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives

    by Piotr Kulig, Sławomir Milczarek, Estera Bakinowska, Laura Szalewska, Bartłomiej Baumert, Bogusław Machaliński

    Multiple myeloma (MM) is the second most common hematologic malignancy, accounting for approximately 1% of all cancers. Despite the initial poor prognosis for MM patients, their life expectancy has improved significantly with the development of novel agents. Immunomodulatory drugs (IMiDs) are widely used in MM therapy. Their implementation has been a milestone in improving the clinical outcomes of patients. The first molecule belonging to the IMiDs was thalidomide. Subsequently, its novel derivatives, lenalidomide (LEN) and pomalidomide (POM), were implemented. Almost all MM patients are exposed to LEN, which is the most commonly used IMiD. Despite the potent anti-MM activity of LEN, some patients eventually relapse and become LEN-resistant. Drug resistance is one of the greatest challenges of modern oncology and has become the main cause of cancer treatment failures. The number of patients receiving LEN is increasing, hence the problem of LEN resistance has become a great obstacle for hematologists worldwide. In this review, we intended to shed more light on the pathophysiology of LEN resistance in MM, with particular emphasis on the molecular background. Moreover, we have briefly summarized strategies to overcome LEN resistance and we have outlined future directions.


  • Open Access

    Secondary Hemophagocytic Syndrome in a Patient with Plasma Cell Myeloma and CNS Involvement Treated with Lenalidomide

    by Sławomir Milczarek, Piotr Kulig, Bartłomiej Baumert, Aleksandra Łanocha, Krzysztof Sommerfeld, Ewa Borowiecka, Bogumiła Osękowska, Edyta Paczkowska, Barbara Zdziarska, Bogusław Machaliński

    We present an extremely rare case report of a 29-year-old multiple myeloma patient with central nervous system involvement and secondary hemophagocytic lymphohistiocytosis (HLH). We observed that HLH was presumably triggered by the immunomodulatory drug—lenalidomide. HLH is frequently misdiagnosed or underdiagnosed. As HLH requires immediate treatment, our report emphasizes the need to consider HLH in the differential diagnosis when the condition of a patient receiving chemotherapy rapidly deteriorates and an infectious etiology is excluded. We furthermore discuss the pathogenesis of HLH, with particular emphasis on drugs affecting the immune system as well as possible therapeutic strategies.


  • Open Access

    Updates for the diagnosis and management of cardiac amyloidosis

    by Piotr Gosciniak, Tomasz Baron, Sławomir Milczarek, Magdalena Kostkiewicz, Bogusław Machaliński

    A substantial increase in the interest in transthyretin cardiac amyloidosis (ATTR-CA) is a result of the constantly growing number of patients, the use of clear diagnostic protocols and the availability of the first selective drug for these patients. This has also raised the awareness of the disease among physicians of all specialties. The topic is particularly relevant to cardiologists, who use non-invasive multimodal imaging in their daily practice. The differential diagnosis of the causes of myocardial hypertrophy includes arterial hypertension, hypertrophic cardiomyopathy, aortic stenosis (AS), athletic heart syndrome, Fabry disease, and cardiac amyloidosis (CA). It turns out that in patients with myocardial hypertrophy >15 mm, amyloidosis is the most common cause of left ventricular (LV) hypertrophy. In parallel, CA is one of the most common infiltrative diseases leading to a clinical picture that may mimic heart failure with preserved ejection fraction (HFpEF). The accumulation of amyloid in the extracellular space impairs the diastolic function of the myocardium, which is observed as the restrictive cardiomyopathy phenotype. In advanced cases, the LV systolic function is also impaired. Moreover, protein deposits contribute to the disturbances of calcium metabolism and cell metabolism as well as to cardiotoxicity, leading to edema and damage to cardiomyocytes.


  • Open Access

    The Impact of the COVID-19 Pandemic on the Organization of Cardio-Hematology Care—A Polish Single Center Experience

    by Piotr Gościniak, Bartłomiej Baumert, Sławomir Milczarek, Joanna Jędrzychowska-Baraniak, Anna Sobuś, Bogusław Machaliński

    Background and Objectives: We present a retrospective report on the cardio-hematological care of hematology patients at a university hospital in Poland during the COVID-19 pandemic. Materials and Methods: The number of hospitalizations at the Hematology Department and cardio-hematology consultations throughout 2019 and 2020 was analyzed. The types of cardiac procedures, risk factors, and complications were also assessed. Results: A significant reduction in the number of hospitalizations was observed in 2020 as compared to 2019. However, there were no significant differences in the incidence of hematological diseases between both of the analyzed years. In 2019, 299 cardiac consultations were performed in hematological patients, and there was a total of 352 such consultations performed in 2020 (p = 0.042). Less high-risk tests (transesophageal and stress echocardiography) were performed in 2020, in favor of the use of cardiac computed tomography in cardiac diagnostics as it was safer during the pandemic. At least one cardiovascular risk factor during cardiac consultation was noted in 42% and 48% of hematological patients in 2019 and 2020, respectively. Among 651 examined hematological patients, the most common findings were mild cardiac complications of hemato-oncological treatment, which were found in 57 patients. Conclusions: This study seems to confirm that during a pandemic there is an increased demand for well-organized cardio-hematology consultations.


  • Open Access

    Case of Patient with AML with Complex Karyotype including Ultra-Rare t(4;8)(q32;q13), t(4;11)(q21;p15) and Familial Aggregation of Myeloid Malignancies

    by Sławomir Milczarek, Ewa Studniak, Bartłomiej Baumert, Michał Janowski, Wioleta Bonda, Joanna Pietrzak, Aleksandra Łanocha, Edyta Paczkowska, Barbara Zdziarska, Bogusław Machaliński

    We present a unique case of a young woman with acute myeloid leukemia (AML) with complex karyotype. The presence of the t(4;11)(q23;p15) is extremely rare in myeloid leukemias, while t(4;8)(q32;q13) has not yet been described in any leukemia reference. Another interesting issue is the familial aggregation of myeloid malignancies and worse course of the disease in each subsequent generation, as well as an earlier onset of the disease. Our report emphasizes the need for thorough pedigree examination upon myeloid malignancy diagnosis as there are relatives for whom counseling, gene testing, and surveillance may be highly advisable.